Fig. 8.

Antitumor effect of combination therapy in an intravenous tumor-bearing model. a Treatment strategy used for combination therapy in an intravenous tumor-bearing model. THP-1 cells (1 × 10⁷) were administered to each mouse intravenously. Recombinant Ad (2 × 10⁸ IU) was administered intravenously each time. Each mouse was administered with 1 × 10⁹ IU recombinant Ad during the entire treatment. Rh2 was administered at 5 mg/kg. Blood samples were drawn on the day before THP-1 cell transplantation and on the 13th, 20th, 27th, 34th, and 41st days after transplantation. All mice were killed 42 days after tumor cell transplantation. b THP-1 cell percentage in the PBMCs of each mouse was detected with an anti-CD33 antibody using flow cytometry. c Kaplan–Meier analysis of animal end point survival after treatment with intravenous zA4, intraperitoneal Rh2, and the combination. d Metastatic THP-1 cells in the liver were detected by immunohistochemistry (IHC) with an anti-CD33 antibody. The scale bar represents 0.1 mm. e The percentages of CD33-positive cells in three microscopic fields were quantified at ×200 magnification (mean ± SEM). Error bars represent the SEM. *P < 0.05; **P < 0.01; ***P < 0.001